Slaughter and May advised Immunocore Limited on its $130 million Series B financing
Slaughter and May advised Immunocore Limited on its Series B equity fundraising. The fundraising completed on 2 March 2020 and generated proceeds of more than $130 million, with both new investors and existing shareholders participating in the fundraising.
Immunocore Limited is a clinical-stage T cell receptor biotechnology company working to develop and commercialise a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease. The proceeds of the fundraising will enable Immunocore Limited to further expand and accelerate the development of its technology.